January 4, 2021 -- Hoth Therapeutics has entered into a nonexclusive license agreement with the U.S. Army Medical Research and Development Command for a new molecular entity with a novel antibacterial mechanism of action developed by the Walter Reed Army Institute of Research.
The molecule (to be called "HT-006") has the potential to treat many different types of bacterial infections. Hoth will initially target serious bacterial infections of the lung, such as hospital-acquired pneumonia and ventilator-associated pneumonia for which current treatment options are limited or not effective against multidrug resistant bacteria.
The company will pursue development opportunities under the U.S. Food and Drug Administration's program for "antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases." This program allows for use of nonclinical animal studies to reduce clinical studies required for approval. Preclinical studies investigating the inhibitory concentration of HT-006 for various multidrug resistant bacterial species are planned to begin in Q1 2021.
Hoth intends to collaborate with various Army research experts and to utilize the Army's medical laboratory resources during the development of HT-006.